WASHINGTON – Two years after the withdrawal of the pain-killer Vioxx, the Food and Drug Administration still can’t adequately track the safety of new drugs and respond quickly to problems, a panel of experts said Friday.
Link to original article
FDA panel narrowly approves Vioxx, but cites risk in drug category
A US health advisory panel confirmed cardiovascular risks from certain anti-inflammatory drugs, but agreed to the return of Vioxx, withdrawn last year, and continued sale of two similar medications whose safety was questioned.
Another drug for pain off market
Since concerns over cardiovascular safety spurred Merck to pull its arthritis drug Vioxx off the market Sept
Lawyer, witness argue at tense Vioxx trial
ATLANTIC CITY Verbal jousting between a defense lawyer and a key plaintiff's witness escalated Tuesday and the judge told attorneys to calm down during the second trial over Merck & Co.'s withdrawn painkiller Vioxx.
Contact:
Copyright © 2005 Vioxx Advisor.com All Rights Reserved